These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 3620354)

  • 1. Fibrinogen Aarhus and factor XIII induced polymerization and gel formation.
    Hessel B; Adamson L; Procyk R; Therkildsen L; Stenbjerg S; Blombäck B
    Br J Haematol; 1987 Jul; 66(3):355-61. PubMed ID: 3620354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinogen Aarhus--a new case of dysfibrinogenemia.
    Hessel B; Stenbjerg S; Dyr J; Kudryk B; Therkildsen L; Blombäck B
    Thromb Res; 1986 Apr; 42(1):21-37. PubMed ID: 2939591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting.
    Greenberg CS; Miraglia CC; Rickles FR; Shuman MA
    J Clin Invest; 1985 May; 75(5):1463-70. PubMed ID: 2860124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinogen Chapel Hill II: defective in reactions with thrombin, factor XIIIa and plasmin.
    Carrell N; McDonagh J
    Br J Haematol; 1982 Sep; 52(1):35-47. PubMed ID: 6126210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the fibrin polymer structure that accelerates thrombin cleavage of plasma factor XIII.
    Greenberg CS; Achyuthan KE; Rajagopalan S; Pizzo SV
    Arch Biochem Biophys; 1988 Apr; 262(1):142-8. PubMed ID: 2895608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinogen Seattle II: defective release of fibrinopeptide A in a slow clotting fibrinogen.
    Schreiber WE; Schmer G
    Thromb Res; 1985 Jan; 37(1):45-52. PubMed ID: 3983901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibronectin and fibrin gel structure.
    Okada M; Blombäck B; Chang MD; Horowitz B
    J Biol Chem; 1985 Feb; 260(3):1811-20. PubMed ID: 2857179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinogen Houston: a dysfibrinogen exhibiting defective fibrin monomer aggregation and alpha-chain cross-linkages.
    Weinger RS; Rudy C; Moake JL; Conlon CL; Cimo PL
    Am J Hematol; 1980; 9(3):237-48. PubMed ID: 6165239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defective alpha-polymerization in the conversion of fibrinogen Baltimore to fibrin.
    Brown CH; Crowe MF
    J Clin Invest; 1975 Jun; 55(6):1190-4. PubMed ID: 1133167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of plasma factor XIII binding to fibrin in vitro.
    Greenberg CS; Dobson JV; Miraglia CC
    Blood; 1985 Nov; 66(5):1028-34. PubMed ID: 2413926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor XIII catalyzed formation of fibrinogen-fibronectin oligomers--a thiol enhanced process.
    Procyk R; Adamson L; Block M; Blombäck B
    Thromb Res; 1985 Dec; 40(6):833-52. PubMed ID: 2868545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor XIII-induced crosslinking in solutions of fibrinogen and fibronectin.
    Procyk R; Blomback B
    Biochim Biophys Acta; 1988 Nov; 967(2):304-13. PubMed ID: 2903773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human fibrinogen and asialo-fibrinogen: a comparison of coagulation parameters.
    Gentry PA; Alexander B
    Arch Biochem Biophys; 1976 Mar; 173(1):50-7. PubMed ID: 176955
    [No Abstract]   [Full Text] [Related]  

  • 14. A hereditary dysfibrinogenemia: fibrinogen Awaji.
    Matsuo T; Okuno S; Mukaida T; Ueshima S; Okada K; Matsuo O
    Haemostasis; 1987; 17(1-2):89-97. PubMed ID: 3596361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intracranial hemorrhage and hemostasis. Monitoring patients after intracranial hemorrhage by determination and follow-up of activation products of blood coagulation].
    Menges T; von Lessen A; Welters I; Wagner RM; Ruwoldt R; Boldt J; Hempelmann G
    Infusionsther Transfusionsmed; 1994 Aug; 21(4):244-50. PubMed ID: 7950289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysfibrinogenaemia characterized by abnormal fibrin monomer polymerization and normal fibrinopeptide A release.
    Lane DA; Cuddigan B; VanRoss M; Kakkar VV
    Br J Haematol; 1980 Mar; 44(3):483-94. PubMed ID: 6769460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysfibrinogenemia associated with liver disease.
    Palascak JE; Martinez J
    J Clin Invest; 1977 Jul; 60(1):89-95. PubMed ID: 874092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymerization and gelation of fibrinogen in D2O.
    Larsson U
    Eur J Biochem; 1988 May; 174(1):139-44. PubMed ID: 3371358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor XIII and its substrates, fibronectin, fibrinogen, and alpha 2-antiplasmin, in plasma and urine of patients with nephrosis.
    Vaziri ND; Gonzales E; Barton CH; Chen HT; Nguyen Q; Arquilla M
    J Lab Clin Med; 1991 Feb; 117(2):152-6. PubMed ID: 1993857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promotion of thrombin-catalyzed activation of factor XIII by fibrinogen.
    Janus TJ; Lewis SD; Lorand L; Shafer JA
    Biochemistry; 1983 Dec; 22(26):6269-72. PubMed ID: 6661434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.